Qihui Huang is a prominent inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer therapeutics, holding a total of 4 patents. His work focuses on developing innovative binding molecules that target CD73, a protein associated with various cancers.

Latest Patents

One of Qihui Huang's latest patents is titled "Binding molecules specific for CD73 and uses thereof." This patent discloses anti-CD73 binding molecules, including antibodies and their antigen-binding fragments. The patent also outlines pharmaceutical formulations that incorporate these compositions, along with methods for diagnosing and treating diseases linked to CD73 expression, such as cancer. The therapies described include direct treatment with the anti-CD73 binding molecules, adjuvant therapy with other anticancer agents, and combination therapies that may involve chemotherapy.

Career Highlights

Qihui Huang is currently associated with MedImmune Limited, where he continues to advance his research in cancer treatment. His innovative approaches have the potential to significantly impact the way cancers are treated, particularly through the use of targeted therapies.

Collaborations

Some of Qihui Huang's notable coworkers include Carl Hay and Kris Sachsenmeier. Their collaborative efforts contribute to the ongoing research and development of effective cancer therapies.

Conclusion

Qihui Huang's work exemplifies the critical role of innovation in the fight against cancer. His patents and research efforts are paving the way for new therapeutic options that could improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.